Correction
for
Osborne et al., J. Natl. Cancer Inst. 95 (5) 353-361.
JNCI Journal of the National Cancer Institute 2003 95(10):763; doi:10.1093/jnci/95.10.763
© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 10, 763,
May 21, 2003
© 2003 Oxford University Press
Erratum
"Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and
HER-2/neu in Tamoxifen Resistance in Breast Cancer" by Osborne
et al. [J Natl Cancer Inst 2003;95:353–61 (Issue 5)].
On page 358, Fig. 2A
was not the correct figure, although the
data in the legend and the text are correct. The correct figure
is as follows. The authors regret the error.
View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2. Kaplan–Meier estimates of disease-free survival (DFS). A) DFS according to AIB1 expression for patients who did not receive adjuvant therapy (n = 119). Patients with high AIB1 expression (top quartile: AIB1>1.67 densitometric units) were compared with patients with lower AIB1 expression ( 1.67 densitometric units). B) DFS curves for patients who did not receive adjuvant therapy (n = 119). Patients with high AIB1 expression (top quartile) and low HER-2 expression were compared with patients with high expression of both AIB1 and HER-2, low expression of both AIB1 and HER-2, or low AIB1 expression and high HER-2 expression. C) DFS for patients who received adjuvant tamoxifen therapy (n = 187). Patients with high AIB1 expression (top quartile) and high HER-2 expression (grades 2–4) were compared with patients with high expression of both AIB1 and HER-2, low expression of both AIB1 and HER-2, or low AIB1 expression and high HER-2 expression. All P values refer to two-sided log-rank tests. Numbers below each graph indicate the number of patients remaining at risk in each group. Vertical lines are the 95% confidence intervals at selected time points.
|
|
CiteULike 
Connotea 
Del.icio.us What's this?
